This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Maraviroc oral

Updated 2 Feb 2023 | Other antiretrovirals


Oral formulations of maraviroc.

Drugs List

  • CELSENTRI 150mg tablets
  • CELSENTRI 20mg/ml oral solution
  • CELSENTRI 300mg tablets
  • maraviroc 150mg tablets
  • maraviroc 20mg/ml oral solution sugar-free
  • maraviroc 300mg tablets
  • Therapeutic Indications


    HIV where only CCR5-tropic HIV-1 detectable: Combination treatment

    Treatment of Human Immunodeficiency Virus (HIV) infection in treatment-experienced patients weighing at least 10kg with only CCR5-tropic HIV-1 detectable.
    Maraviroc must be given in combination with other antiretroviral medicines.


    Before taking maraviroc, it must be established that only CCR5-tropic HIV-1 is detectable (i.e. CXCR4 or dual/mixed tropic virus not detected). An adequately validated and sensitive detection method on a newly drawn sample of blood should be used. The viral tropism cannot be safely predicted based on treatment history and assessment of stored blood samples.

    Therapy should be started shortly after a tropism test as changes in viral tropism occur over time in patients with HIV.

    The dose will depend on the interactions with concurrent antiretroviral therapy and other medicinal products.


    300mg twice daily.

    With concomitant potent CYP3A4 inducers
    600mg twice daily.

    With concomitant potent CYP3A4 inhibitors (with or without a potent CYP3A inducer)
    150mg twice daily.


    Children from 2 years of age and weighing at least 10kg
    30kg and over: 300mg twice daily.
    Less than 30kg: not recommended.

    With concomitant potent CYP3A4 inducers
    Not recommended.

    With concomitant potent CYP3A4 inhibitors (with or without a potent CYP3A inducer)
    40kg and over: 150mg twice daily.
    30kg to less than 40kg: 100mg twice daily.
    20kg to less than 30kg: 75mg twice daily.
    10kg to less than 20kg: 50mg twice daily.

    Patients with Renal Impairment

    Creatinine clearance below 80ml/minute with concomitant use of potent CYP3A4 inhibitor use
    150mg once daily.


    Children under 2 years
    Children weighing less than 10kg

    Precautions and Warnings

    Patients over 65 years
    Hepatic impairment
    Hepatitis B
    Hepatitis C
    History of postural hypotension
    Renal impairment - creatinine clearance below 80ml/min
    Severe cardiovascular disorder

    Treatment does not prevent risk of transmission of HIV
    Advise patient dizziness may affect ability to drive or operate machinery
    Confirm CCR5-tropic HIV-1 status prior to treatment
    Must be used in combination with other antiretrovirals
    Treatment should be initiated by doctor experienced in HIV management
    Contains arachis (peanut oil), soya or soya derivative
    Autoimmune disorders can occur many months after initiation of treatment
    Monitor closely patient with pre-existing hepatic impairment
    Start therapy shortly after viral tropism test- changes can occur over time
    Advise patient to seek medical advice if joint aches or pain occur
    Advise patient to seek medical advice if movement becomes difficult
    Consider discontinuing treatment if hepatotoxicity occurs
    Inflammatory symptoms should be evaluated and treated appropriately
    Risk of developing opportunistic infections
    Discontinue if drug-related rash or other hypersensitivity reactions occur
    Advise patient not to take St John's wort concurrently

    There are no data regarding the re-use of maraviroc in patients with only CCR5-tropic HIV-1 detectable, but have a history of failure on maraviroc (or other CCR5 antagonists) with a CXCR4 or dual/mixed tropic virus. There are no data on switching to maraviroc from a different antiretroviral class in virologically suppressed patients. Alternative treatment options should be considered.

    It is recommended that maraviroc should not be used in treatment naive patients.

    Use with caution in patients with a history of postural hypotension and in patients taking concurrent blood pressure lowering medications. Symptomatic cases of postural hypotension have been seen in healthy volunteers at doses above the recommended dose.

    Cases of osteonecrosis have been reported, particularly in patients with advanced HIV disease and/or long term exposure to combination antiretroviral therapy. The aetiology of this condition is thought to be due to several factors including corticosteroid use, alcohol consumption, severe immunosuppression, and higher body mass index. Patients should be advised to seek medical advice if they experience joint aches or pains, joint stiffness or difficulty in movement.

    There is an increased risk of postural hypotension in patients with severe renal impairment who also use protease inhibitors which may lead to cardiovascular adverse effects.

    Pregnancy and Lactation


    Use maraviroc with caution in pregnancy.

    At the time of writing there is limited published information regarding the use of maraviroc during pregnancy. The manufacturer indicates that maraviroc should be only used in pregnancy if the expected benefit outweighs the potential risk to the foetus.

    Maraviroc is known to cross the placenta. Animal studies have shown reproductive toxicity at high exposures.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Maraviroc is contraindicated in breastfeeding.

    It is recommended that mothers infected by HIV do not breast-feed under any circumstances, in order to avoid transmission of HIV. Maraviroc use in breastfeeding is contraindicated by the manufacturer.

    It is not known if maraviroc is excreted into human breast milk. The drug's molecular weight and long elimination half life suggest that the drug would be excreted into the breast milk. The effect on a nursing infant is unknown. Animal studies have indicated that maraviroc is extensively secreted in milk.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal distension
    Abdominal pain
    Alanine aminotransferase increased
    Angina pectoris
    Aspartate aminotransferase increased
    Autoimmune hepatitis
    Back pain
    Bile duct cancer
    Creatine phosphokinase increased
    Gamma glutamyl transferase (GGT) increased
    Graves' disease
    Hepatic failure
    Hodgkin's disease
    Increase in alkaline phosphatase
    Metastatic disease
    Muscular atrophy
    Oesophageal candidiasis
    Oesophageal carcinoma
    Opportunistic infections
    Postural hypotension
    Renal failure
    Stevens-Johnson syndrome
    Toxic epidermal necrolysis
    Toxic hepatitis


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: April 2018.

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Celsentri 25mg, 75mg, 150mg and 300mg film-coated tablets. ViiV Healthcare UK Ltd. Revised September 2018.
    Summary of Product Characteristics: Celsentri 20mg/ml oral solution. ViiV Healthcare UK Ltd. Revised September 2018.

    NICE Evidence Services Available at: Last accessed: Aprl 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.